Please try another search
For the fiscal year ended 30 September 2012, HemagenDiagnostics, Inc. revenues decreased 21% to $4M. Net lossincreased 3% to $907K. Revenues reflect Brazil segmentdecrease of 36% to $1.5M, United States segment decrease of9% to $2.5M. Higher net loss reflects Interest Expense Netincrease of 15% to $469K (expense), Research anddevelopment increase from $5K to $45K (expense).
Period Ending: | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 |
---|---|---|---|---|
Total Revenue | 0.88 | 0.95 | 1.11 | 1.11 |
Gross Profit | 0.4 | 0.45 | 0.35 | 0.41 |
Operating Income | -0.04 | -0.01 | -0.13 | -0.25 |
Net Income | -0.16 | -0.13 | -0.24 | -0.37 |
Period Ending: | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 |
---|---|---|---|---|
Total Assets | 2.44 | 2.52 | 2.59 | 2.59 |
Total Liabilities | 6 | 5.96 | 5.84 | 5.63 |
Total Equity | -3.56 | -3.43 | -3.24 | -3.04 |
Period Ending: | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -0.36 | -0.31 | -0.32 | -0.21 |
Cash From Investing Activities | -0.06 | -0.05 | -0.04 | -0.03 |
Cash From Financing Activities | 0.31 | 0.31 | 0.23 | 0.05 |
Net Change in Cash | -0.15 | -0.11 | -0.13 | -0.19 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review